Xspray Pharma (XSPRAY.ST)

Executive Summary

Xspray Pharma is a Swedish oncology-focused company leveraging its proprietary HyNap technology to develop amorphous formulations of marketed Protein Kinase Inhibitors (PKIs). By enhancing solubility and reducing pharmacokinetic variability, its products aim to improve efficacy, safety, and patient quality of life. The lead candidate, Dasynoc (dasatinib), targets chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a validated technology platform and a streamlined regulatory pathway (505(b)(2) in the US), the company is nearing a critical inflection point as it prepares for commercial launch.

Upcoming Catalysts (preview)

• Q2 2026FDA approval decision for Dasynoc (dasatinib)75% success
• Q4 2026European Medicines Agency (EMA) marketing authorization application submission65% success
• TBDPotential partnership or licensing deal for Dasynoc in ex-US markets50% success